Article Text

Download PDFPDF
Price promotion receipt and use progression of any tobacco, cigarettes, e-cigarettes and cigars among US youth between 2016 and 2018
  1. Julia Chen-Sankey1,
  2. Jennifer B Unger2,
  3. Edward Bernat3,
  4. Jeff Niederdeppe4,
  5. Maansi Bansal-Travers5,
  6. Kelvin Choi1
  1. 1 Division of Intramural Research, National Institute on Minority Health and Health Disparities, Bethesda, Maryland, USA
  2. 2 Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California, USA
  3. 3 Department of Psychology, University of Maryland, College Park, Maryland, USA
  4. 4 Department of Communication, Cornell University, Ithaca, New York, USA
  5. 5 Health Behavior, Roswell Park Cancer Institute, Buffalo, New York, USA
  1. Correspondence to Dr Julia Chen-Sankey, National Institute on Minority Health and Health Disparities, Bethesda, MD 20892, USA; Julia.Chen-Sankey{at}nih.gov

Abstract

Background Tobacco price promotions may prompt tobacco trials among youth. We assessed whether receiving price promotions for any tobacco, cigarettes, e-cigarettes and cigars was associated with product use progression.

Methods The analysis included a nationally representative sample of youth never tobacco users (aged 12–16; n=9405) from wave 4 (2016–2018) of the Population Assessment of Tobacco and Health Study. We assessed past-year receipt of price promotions and use progression (initiation, current use and ever regular use) for any tobacco, cigarettes, e-cigarettes and cigars 1 year later at wave 4.5 (2017–2018). Multivariable logistic regressions were used to examine the associations between receiving price promotions and use progression by product type, controlling for covariates.

Results At wave 4.5, 9.4% of youth initiated any tobacco (1.8%, 7.8% and 0.9% for cigarettes, e-cigarettes and cigars), and 5.4% received any price promotions (3.8%, 3.1% and 0.9% for cigarettes, e-cigarettes and cigars). Receiving any tobacco price promotions was associated with any tobacco initiation (adjusted OR (AOR)=1.77; 95% CI 1.30 to 2.41), current use (AOR=1.54; 95% CI 1.06 to 2.23) and ever regular use (AOR=1.76; 95% CI 1.04 to 3.10). Receiving e-cigarette price promotions was associated with e-cigarette initiation (AOR=1.78; 95% CI 1.18 to 2.26), current use (AOR=1.88; 95% CI 1.17 to 3.02) and ever regular use (AOR=2.10; 95% CI 1.02 to 4.40). The associations specific to cigarettes and cigars were only found for product initiation.

Discussion Receiving price promotions for any tobacco and e-cigarettes was respectively associated with the use progression of any tobacco and e-cigarettes. Continuous monitoring of tobacco marketing activities is needed to identify youth-appealing price promotion tactics.

  • advertising and promotion
  • non-cigarette tobacco products
  • prevention

Data availability statement

All data relevant to the study are included in the article or uploaded as supplementary information.

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Data availability statement

All data relevant to the study are included in the article or uploaded as supplementary information.

View Full Text

Footnotes

  • Contributors Concept and design: JCS, KC. Acquisition, analysis or interpretation of data: all authors. Drafting of the manuscript: JCS. Critical revision of the manuscript for important intellectual content: all authors. Statistical analysis: JCS. Obtained funding: JCS, KC. Administrative, technical or material support: JCS, KC. Supervision: JCS, KC.

  • Funding JCS is supported by NCI/FDA grant K99CA242589. JCS and KC are supported by the Division of Intramural Research, National Institute on Minority Health and Health Disparities.

  • Disclaimer Comments and opinions expressed belong to the authors and do not necessarily represent the views of the US Government, National Institutes of Health, National Cancer Institute, or the Institute on Minority Health and Health Disparities, or the FDA.

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; externally peer reviewed.